Novartis Venture Fund — Seed & Series A VC Firm ($2.0M–$15.0M Checks)
Novartis Venture Fund is a Seed, Series A venture capital firm based in Europe, United States investing in Healthcare, EdTech. The firm typically writes $2.0M–$15.0M checks and has 37 portfolio companies in our records.
- Check size
- $2.0M–$15.0M
- Portfolio
- 37 companies on record
- Partners
- 1 listed
- AUM
- $1B
- Stage
- Seed, Series A
- Sectors
- Healthcare, EdTech
- HQ
- Europe, United States
Last verified: 2026-10-25
Seed, Series A
$2.0M – $15.0M
$1.0B
37+ companies
1 partner
Investment Thesis
Invests in innovative life science companies in biotechnology and biopharmaceuticals addressing unmet patient needs. Best for science-heavy biotech, though the check size may be above the lower end of the target range.
How Novartis Venture Fund invests
Novartis Venture Fund is a vc firm based in Europe, United States. The firm invests at the Seed, Series A stages, with a focus on Healthcare, EdTech.
Novartis Venture Fund typically writes checks of $2.0M–$15.0M per investment, backed by approximately $1B in assets under management. Our records include 3 funds raised by the firm.
Novartis Venture Fund has backed 37 companies in our records, including Epi Biologics, Epsilogen, Fore Biotherapeutics.
Partners & Team
Unknown
Partner
Industry Focus
Invests In
Funds
Novartis Venture Fund III
Novartis Venture Fund II
Novartis Venture Fund
Recent Activity
Raised Novartis Venture Fund III ($200M)
2021 · fund records
Raised Novartis Venture Fund II ($150M)
2016 · fund records
Raised Novartis Venture Fund ($100M)
2011 · fund records
Portfolio Companies (37)
Other
Epi Biologics
Develops targeted protein degradation therapies.
Epsilogen
Develops IgE antibody therapies for cancer.
Fore Biotherapeutics
Develops precision oncology therapeutics.
Salvina
Develops therapeutics in life sciences.
Ablation Frontiers
Medical device company focused on cardiac ablation technologies.
Adenosine Therapeutics
Biopharma company focused on adenosine-pathway therapies.
Arctos Medical
Medical device company later acquired by Novartis.
Amphista Therapeutics
Develops targeted protein degradation therapeutics.
Anaveon
Develops immunotherapy candidates for cancer and immune-related diseases.
Aravax
Develops peptide-based therapies for food allergies.
- •Raising at Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare, EdTech — the sectors they actively back.
- •Size your ask to their typical $2.0M – $15.0M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Unknown, Partner.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Novartis Venture Fund is a match for your startup
Upload your pitch deck to see how well you match with Novartis Venture Fund and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal